Enhabit, Inc. (NYSE:EHAB) Given Average Rating of “Reduce” by Analysts

Enhabit, Inc. (NYSE:EHAB) has earned an average rating of “Reduce” from the eight research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $9.79.

EHAB has been the topic of a number of research reports. UBS Group raised Enhabit from a “sell” rating to a “neutral” rating and set a $9.50 price objective on the stock in a report on Thursday, March 7th. SVB Leerink raised shares of Enhabit from an “underperform” rating to a “market perform” rating and set a $8.50 price target for the company in a research report on Tuesday, May 14th. Leerink Partnrs raised shares of Enhabit from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 14th. Oppenheimer reissued a “market perform” rating on shares of Enhabit in a report on Thursday, March 7th. Finally, Bank of America decreased their target price on shares of Enhabit from $9.00 to $8.00 and set an “underperform” rating for the company in a research report on Thursday, June 27th.

Enhabit Stock Performance

Shares of Enhabit stock opened at $8.78 on Tuesday. The firm has a market capitalization of $440.40 million, a P/E ratio of -5.29, a PEG ratio of 1.43 and a beta of 1.86. Enhabit has a 52 week low of $7.12 and a 52 week high of $14.59. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.75. The company has a 50 day moving average price of $9.16 and a 200 day moving average price of $9.85.

Enhabit (NYSE:EHAB) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.05 by $0.02. Enhabit had a negative net margin of 7.95% and a positive return on equity of 1.43%. The business had revenue of $262.40 million during the quarter, compared to the consensus estimate of $268.25 million. Sell-side analysts expect that Enhabit will post 0.24 EPS for the current year.

Insiders Place Their Bets

In other Enhabit news, Director Jeffrey Bolton bought 10,000 shares of the company’s stock in a transaction dated Friday, May 17th. The shares were purchased at an average cost of $8.33 per share, for a total transaction of $83,300.00. Following the transaction, the director now directly owns 52,299 shares of the company’s stock, valued at $435,650.67. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders bought 22,000 shares of company stock worth $183,700. Company insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Enhabit

A number of institutional investors have recently added to or reduced their stakes in EHAB. Scopia Capital Management LP lifted its holdings in Enhabit by 9.3% during the third quarter. Scopia Capital Management LP now owns 2,091,315 shares of the company’s stock valued at $23,527,000 after purchasing an additional 177,400 shares in the last quarter. JANA Partners Management LP acquired a new stake in Enhabit in the 3rd quarter worth about $20,532,000. Schroder Investment Management Group increased its stake in Enhabit by 0.8% during the 3rd quarter. Schroder Investment Management Group now owns 1,685,885 shares of the company’s stock worth $18,966,000 after buying an additional 13,387 shares in the last quarter. UBS Group AG raised its holdings in shares of Enhabit by 2.0% during the fourth quarter. UBS Group AG now owns 1,666,362 shares of the company’s stock valued at $17,247,000 after acquiring an additional 32,611 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Enhabit by 25.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 966,515 shares of the company’s stock valued at $10,003,000 after acquiring an additional 193,675 shares in the last quarter.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.